Trial Profile
Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Clinical Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Aug 2023
Price :
$35
*
At a glance
- Drugs Semaglutide (Primary) ; Metformin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SEPRA
- Sponsors Novo Nordisk
- 21 Jul 2023 Status changed from active, no longer recruiting to completed.
- 26 Jun 2023 Primary endpoint has been met, (Hemoglobin A1c (HbA1c) less than 7.0% (53 mmol/mol) (yes/no), as per Results presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
- 26 Jun 2023 Results presented at the 83rd Annual Scientific Sessions of the American Diabetes Association